Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734059 | 1.00 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1735087 | 0.91 | EPHX1 (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1736334 | 0.91 | GRIN2D (0.30) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1735086 | 0.91 | EPHX1 (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1736335 | 0.91 | GRIN2D (0.30) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1736305 | 0.85 | — | — | |
| SCHEMBL1736302 | 0.85 | — | — | |
| SCHEMBL1736345 | 0.81 | — | — | |
| SCHEMBL1736344 | 0.81 | — | — | |
| SCHEMBL1735190 | 0.80 | KMT2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794548-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2019-05-15 | — | — | EP | claimed |
| US-9382190-B2 | Continuous process for the carbonylation of ethylene | LUCITE INTERNATIONAL UK LIMITED (GB) | 2016-07-05 | — | — | US | claimed |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-04-09 | — | — | US | claimed |
| EP-2007703-B1 | METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INT UK LTD (GB) | 2013-12-18 | — | — | EP | claimed |
| US-8445711-B2 | Metal complexes | LUCITE INTERNATIONAL UK LIMITED (GB) | 2013-05-21 | — | — | US | claimed |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-08-05 | — | — | US | claimed |
| US-20090312561-A1 | METAL COMPLEXES | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-12-17 | — | — | US | claimed |
| US-20090163724-A1 | Carbonylation of Ethylenically Unsaturated Compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-06-25 | — | — | US | claimed |
| EP-1957198-A1 | CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Lucite International UK Limited (GB) | 2008-08-20 | — | — | EP | claimed |
| WO-2007057640-A1 | CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| EP-1957198-B1 | CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INT UK LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-9382190-B2 | Continuous process for the carbonylation of ethylene | LUCITE INTERNATIONAL UK LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-9334227-B2 | Carbonylation of ethylenically unsaturated compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9138694-B2 | Mixing apparatus | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-09-22 | — | — | US | disclosed |
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20090312561-A1 | METAL COMPLEXES | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090208390-A1 | MIXING APPARATUS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090163724-A1 | Carbonylation of Ethylenically Unsaturated Compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1957198-A1 | CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Lucite International UK Limited (GB) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007057640-A1 | CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099896-A1 | CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | SCD, ELOVL6, ALK | GRIN2D 4632/4885GRIN3B 4616/4885GRIN1 4715/4885 |
| US-20090163724-A1 | Carbonylation of Ethylenically Unsaturated Compounds | CBR3, ETFA, ACOX3 | GRIN2D 2787/4885GRIN3B 2366/4885GRIN1 3438/4885 |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | ALOX5, ACSL5, ELOVL5 | GRIN2D 3509/4885GRIN3B 3042/4885GRIN1 2819/4885 |
| US-20090312561-A1 | METAL COMPLEXES | MLX, PICALM, AP2M1 | GRIN2D 2081/4885GRIN3B 954/4885GRIN1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.